Albiglutide: Is a better hope against diabetes mellitus?

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Arun K SharmaSatyendra K Rajput

Abstract

Type-2 diabetes mellitus (T2DM) is the chronic metabolic disorder which provokes several pitfall signalling. Though, a series of anti-diabetic drugs are available in the market but T2DM is still a huge burden on the developed and developing countries. Numerous studies and survey predict the associated baleful circumstances in near future due to incessant increase in this insidious disorder. The novelty of recent explored anti-diabetic drugs including glitazone, glitazaar and gliflozines seems to be vanished due to their associated toxic side effects. Brown and Dryburgh (1970) isolated an intestinal amino acid known as gastric inhibitory peptide (GIP) which had insulinotropic activity. Subsequently in 1985, another incretin glucagon likes peptide 1 (GLP-1) having potent insulinotropic properties was discovered by Schmidt and his co-workers. On the basis of results' obtained by Phase III Harmony program FDA approved (14 April, 2014) new GLP-1 agonist 'Albiglutide (ALB)', in addition to exiting components Exenatide (Eli Lilly, 2005) and Liraglutide (Novo Nordisk, 2010). ALB stimulates the release of protein kinase A (PKA) via different mechanisms which ultimately leads to increase in intracellular Ca(2+) levels. This increased int...Continue Reading

References

Aug 1, 1971·Canadian Journal of Biochemistry·J C Brown, J R Dryburgh
Feb 26, 2003·The Journal of General Physiology·Lena EliassonPatrik Rorsman
Aug 20, 2003·Nature Medicine·Matthew J DuringColin N Haile
Oct 17, 1964·Lancet·F BALSANOV DINOTO
Jan 19, 2005·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·C F Deacon
Feb 21, 2006·The Journal of Pharmacology and Experimental Therapeutics·Tingcun ZhaoRichard P Shannon
Sep 25, 2008·The Journal of Clinical Endocrinology and Metabolism·Jessica E MatthewsUNKNOWN Albiglutide Study Group
Apr 7, 2010·Expert Opinion on Biological Therapy·Erin L St Onge, Shannon A Miller
Sep 14, 2010·British Journal of Clinical Pharmacology·Milan K PiyaAnthony H Barnett
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jg Karam, Si McFarlane
Apr 13, 2011·Diabetes/metabolism Research and Reviews·Vanita R Aroda, Robert Ratner
Apr 14, 2011·The Annals of Pharmacotherapy·Phillip H LeeAndrea S Franks
Nov 15, 2011·Diabetes Research and Clinical Practice·David R WhitingJonathan Shaw
Dec 20, 2011·Cell Calcium·Patrik RorsmanQuan Zhang
Mar 7, 2012·Pharmacotherapy·Yaman KaakehJames Sutton
Oct 30, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Yumei YeYochai Birnbaum
Feb 5, 2013·European Journal of Internal Medicine·Krzysztof LabuzekBogusław Okopień
Feb 7, 2013·Cellular Signalling·Arun Kumar Sharma, Deepa Khanna
Aug 10, 2013·European Journal of Clinical Pharmacology·Siddesh JaimanDeepa Khanna
Dec 7, 2013·Mediators of Inflammation·Alessandra PudduGiorgio L Viviani
Dec 25, 2013·The American Journal of Dermatopathology·Shi-Jun Shan, Ying Guo
Feb 26, 2014·World Journal of Diabetes·Bo Ahrén
May 3, 2014·Diabetes·Manuel Gil-LozanoPatricia L Brubaker
Jun 12, 2014·Postgraduate Medicine·Malcolm A YoungRickey R Reinhardt
Jun 14, 2014·Patient Preference and Adherence·Heather N Woodward, Sarah L Anderson
Jul 19, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Borje DarpoRickey R Reinhardt

❮ Previous
Next ❯

Citations

Dec 3, 2016·Therapeutic Advances in Drug Safety·Nidhi JainChristopher W Sands
Apr 3, 2018·Chemical & Pharmaceutical Bulletin·Kotaro KimuraMasaki Otagiri
Nov 19, 2018·Cardiovascular Toxicology·Gaurav TanejaArun K Sharma
Mar 31, 2021·Drug Discovery Today·Farah DeebaManju Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.